SCHEMBL3683152

SCHEMBL3683152

CN(O)C(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
CA12 O43570 6/20 0.38
CA1 P00915 6/20 0.38
CA2 P00918 6/20 0.38
CA14 Q9ULX7 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 4/20 0.37
EPHX1 P07099 1/20 0.37
MALT1 Q9UDY8 1/20 0.35
AKT1 P31749 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1328516 0.86 TDP1 (0.46) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL268678 0.81 TDP1 (0.42) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL21887790 0.81 MEN1 (0.43) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL18176811 0.79 TDP1 (0.43) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL19981641 0.79 ALDH1A1 (0.46) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL1456111 0.79 MEN1 (0.41) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL22812721 0.79 MEN1 (0.41) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL31270901 0.78 CA12 (0.43) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL4714065 0.77 TDP1 (0.52) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL125503 0.77 TDP1 (0.52) TDP1MAOAMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-2927224-A1 Receptor antagonists Proximagen Limited (GB) 2015-10-07 EP disclosed
US-7662856-B2 Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine THE UNIVERSITY OF HOUSTON SYSTEM (US) 2010-02-16 US disclosed
US-20080249181-A1 Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine KOHN HAROLD 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249181-A1 Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine CD68, HAAO, HOGA1 TDP1 1215/4885MAOA 225/4885MAOB 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.